학술논문
Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial
Document Type
Article
Author
Orkin, Chloe; Molina, Jean-Michel; Negredo, Eugenia; Arribas, José R; Gathe, Joseph; Eron, Joseph J; Van Landuyt, Erika; Lathouwers, Erkki; Hufkens, Veerle; Petrovic, Romana; Vanveggel, Simon; Opsomer, Magda; Ajana, F; Arribas, JR; Bailey, J; Benson, P; Berenguer, J; Bhatti, L; Blaxhult, A; Brar, I; Bredeek, UF; Brinson, C; Brunetta, J; Casado, J; Clarke, A; Conway, B; Cotte, L; Crofoot, G; Cunningham, D; de Vente, J; De Wit, S; DeJesus, E; Dietz, C; Dretler, R; Eron, J; Fehr, J; Felizarta, F; Fichtenbaum, C; Flamholc, L; Florence, E; Galindo, MJ; Gallant, J; Gasiorowski, J; Gatell, JM; Gathe, J; Gazzard, BG; Girard, P-M; Gisslèn, M; Gutierrez, F; Gutierrez, MDM; Hagins, D; Halota, W; Henn, S; Henry, WK; Horban, A; Huhn, G; Iribarren, JA; Jain, M; Johnson, MA; Katlama, C; Klein, M; Knobel, H; Lucasti, C; Martorell, C; McDonald, C; Mills, A; Molina, J-M; Morales-Ramirez, J; Mounzer, K; Moutschen, M; Murphy, D; Nahass, R; Negredo, E; Olivet, H; Orkin, C; Osiyemi, O; Perez-Valero, I; Piekarska, A; Pineda, JA; Podzamczer, D; Poizot-Martin, I; Portilla Sogorb, J; Post, F; Prelutsky, D; Pulido, F; Rachlis, A; Raffi, F; Ramgopal, M; Rashbaum, B; Rauch, A; Rey, D; Reynes, J; Ricart, C; Richmond, G; Rivero, A; Ruane, P; Gil, I Santos; Scarsella, A; Scribner, A; Shafran, S; Shalit, P; Shamblaw, D; Slim, J; Stoeckle, M; Tashima, K; Teicher, E; Thalme, A; Ustianowski, A; Van Wijngaerden, E; Vandekerckhove, L; Vandercam, B; Voskuhl, G; Walmsley, S; Ward, D; Waters, L; Wilkin, A; Witor, A; Yazdanpanah, Y
Source
The Lancet HIV; January 2018, Vol. 5 Issue: 1 pe23-e34, 12p
Subject
Language
ISSN
24054704; 23523018
Abstract
Simplified regimens with reduced pill burden and fewer side-effects are desirable for people living with HIV. We investigated the efficacy and safety of switching to a single-tablet regimen of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide versus continuing a regimen of boosted protease inhibitor, emtricitabine, and tenofovir disoproxil fumarate.